Related Experiment Video
Updated: Jun 12, 2026

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease
Published on: December 20, 2017
[Diagnosis, assessment, and treatment guideline for Fabry disease]
Abstract:
Fabry disease is infrequent and thus, is still largely unknown to an important part of both the general and medical population. Diagnosis is difficult, and, since it is usually detected in advanced stages, it tends to be associated with important morbidity and a poor prognosis. Knowledge of the disease has developed considerably in the last decades, and recently, the availability of a specific therapy has modified patients' prognosis considerably. In 2008 GMEEF was created as a group of Mexican physicians with specific qualifications for the management of Fabry disease, who decided to establish the following guidelines to address our country's needs, in order to increase the knowledge and develop uniform criteria for the management of Fabry disease patients.
More Related Videos
05:56Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis
Published on: August 29, 2025
06:35Ultrasound Assessment of Endothelial Function: A Technical Guideline of the Flow-mediated Dilation Test
Published on: April 27, 2016
Related Concept Videos
Ultrasound II: Endoscopic Ultrasound and FibroScan
Endoscopic Ultrasound (EUS):
Cystic Fibrosis: Management
Sinus disease and chronic sinusitis...
Nephrotic Syndrome II : Assessment and Medical Management
Chronic Pancreatitis II: Collaborative Care
Assessment:
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
Atherosclerosis III: Management